StockDuty ← Dashboard Nov 01, 2026 10:51 PM ET
SignalFDA/Bio

Shanghai Junshi Biosciences (SEHK:1877) Reaches Three Phase 3 Cancer Trial Milestones

Three Phase 3 cancer trial milestones reached by Shanghai Junshi Biosciences.

What happened: Shanghai Junshi Biosciences (SEHK:1877) reported first patient dosing in a phase 3 trial of JS207/JS007 for advanced hepatocellular carcinoma and began dosing in a separate phase 3 study of JS203 in relapsed or refractory diffuse large B cell lymphoma. Why it matters: The company said the trials remain in the investment phase, so pipeline strength does not yet answer how durable eventual oncology revenues could be. Material impact depends on phase 3 readouts and regulatory traction.
Shanghai Junshi Biosciences (SEHK:1877) reported first patient dosing in a phase 3 trial of JS207/JS007 for advanced hepatocellular carcinoma and began dosing in a separate phase 3 study of JS203 in relapsed or refractory diffuse large B cell lymphoma.
The company said the trials remain in the investment phase, so pipeline strength does not yet answer how durable eventual oncology revenues could be. Material impact depends on phase 3 readouts and regulatory traction.
Sources